Your browser doesn't support javascript.
loading
Impact of initial FDG-PET/CT and serum-free light chain on transformation of conventionally defined solitary plasmacytoma to multiple myeloma.
Fouquet, Guillemette; Guidez, Stéphanie; Herbaux, Charles; Van de Wyngaert, Zoé; Bonnet, Sarah; Beauvais, David; Demarquette, Hélène; Adib, Salim; Hivert, Bénédicte; Wemeau, Mathieu; Berthon, Céline; Terriou, Louis; Coiteux, Valérie; Macro, Margaret; Decaux, Olivier; Facon, Thierry; Huglo, Damien; Leleu, Xavier.
Affiliation
  • Fouquet G; Authors' Affiliations: Service des maladies du sang; Médecine nucléaire, Hôpital Huriez, CHRU, Lille; Hématologie, Hôpital Côte de Nacre, CHU, Caen; Hématologie, Hôpital Sud, CHU, Rennes, France.
  • Guidez S; Authors' Affiliations: Service des maladies du sang; Médecine nucléaire, Hôpital Huriez, CHRU, Lille; Hématologie, Hôpital Côte de Nacre, CHU, Caen; Hématologie, Hôpital Sud, CHU, Rennes, France.
  • Herbaux C; Authors' Affiliations: Service des maladies du sang; Médecine nucléaire, Hôpital Huriez, CHRU, Lille; Hématologie, Hôpital Côte de Nacre, CHU, Caen; Hématologie, Hôpital Sud, CHU, Rennes, France.
  • Van de Wyngaert Z; Authors' Affiliations: Service des maladies du sang; Médecine nucléaire, Hôpital Huriez, CHRU, Lille; Hématologie, Hôpital Côte de Nacre, CHU, Caen; Hématologie, Hôpital Sud, CHU, Rennes, France.
  • Bonnet S; Authors' Affiliations: Service des maladies du sang; Médecine nucléaire, Hôpital Huriez, CHRU, Lille; Hématologie, Hôpital Côte de Nacre, CHU, Caen; Hématologie, Hôpital Sud, CHU, Rennes, France.
  • Beauvais D; Authors' Affiliations: Service des maladies du sang; Médecine nucléaire, Hôpital Huriez, CHRU, Lille; Hématologie, Hôpital Côte de Nacre, CHU, Caen; Hématologie, Hôpital Sud, CHU, Rennes, France.
  • Demarquette H; Authors' Affiliations: Service des maladies du sang; Médecine nucléaire, Hôpital Huriez, CHRU, Lille; Hématologie, Hôpital Côte de Nacre, CHU, Caen; Hématologie, Hôpital Sud, CHU, Rennes, France.
  • Adib S; Authors' Affiliations: Service des maladies du sang; Médecine nucléaire, Hôpital Huriez, CHRU, Lille; Hématologie, Hôpital Côte de Nacre, CHU, Caen; Hématologie, Hôpital Sud, CHU, Rennes, France.
  • Hivert B; Authors' Affiliations: Service des maladies du sang; Médecine nucléaire, Hôpital Huriez, CHRU, Lille; Hématologie, Hôpital Côte de Nacre, CHU, Caen; Hématologie, Hôpital Sud, CHU, Rennes, France.
  • Wemeau M; Authors' Affiliations: Service des maladies du sang; Médecine nucléaire, Hôpital Huriez, CHRU, Lille; Hématologie, Hôpital Côte de Nacre, CHU, Caen; Hématologie, Hôpital Sud, CHU, Rennes, France.
  • Berthon C; Authors' Affiliations: Service des maladies du sang; Médecine nucléaire, Hôpital Huriez, CHRU, Lille; Hématologie, Hôpital Côte de Nacre, CHU, Caen; Hématologie, Hôpital Sud, CHU, Rennes, France.
  • Terriou L; Authors' Affiliations: Service des maladies du sang; Médecine nucléaire, Hôpital Huriez, CHRU, Lille; Hématologie, Hôpital Côte de Nacre, CHU, Caen; Hématologie, Hôpital Sud, CHU, Rennes, France.
  • Coiteux V; Authors' Affiliations: Service des maladies du sang; Médecine nucléaire, Hôpital Huriez, CHRU, Lille; Hématologie, Hôpital Côte de Nacre, CHU, Caen; Hématologie, Hôpital Sud, CHU, Rennes, France.
  • Macro M; Authors' Affiliations: Service des maladies du sang; Médecine nucléaire, Hôpital Huriez, CHRU, Lille; Hématologie, Hôpital Côte de Nacre, CHU, Caen; Hématologie, Hôpital Sud, CHU, Rennes, France.
  • Decaux O; Authors' Affiliations: Service des maladies du sang; Médecine nucléaire, Hôpital Huriez, CHRU, Lille; Hématologie, Hôpital Côte de Nacre, CHU, Caen; Hématologie, Hôpital Sud, CHU, Rennes, France.
  • Facon T; Authors' Affiliations: Service des maladies du sang; Médecine nucléaire, Hôpital Huriez, CHRU, Lille; Hématologie, Hôpital Côte de Nacre, CHU, Caen; Hématologie, Hôpital Sud, CHU, Rennes, France.
  • Huglo D; Authors' Affiliations: Service des maladies du sang; Médecine nucléaire, Hôpital Huriez, CHRU, Lille; Hématologie, Hôpital Côte de Nacre, CHU, Caen; Hématologie, Hôpital Sud, CHU, Rennes, France.
  • Leleu X; Authors' Affiliations: Service des maladies du sang; Médecine nucléaire, Hôpital Huriez, CHRU, Lille; Hématologie, Hôpital Côte de Nacre, CHU, Caen; Hématologie, Hôpital Sud, CHU, Rennes, France xavier.leleu@chru-lille.fr.
Clin Cancer Res ; 20(12): 3254-60, 2014 Jun 15.
Article in En | MEDLINE | ID: mdl-24714772
ABSTRACT

PURPOSE:

Solitary plasmacytoma (SP) is a localized proliferation of monoclonal plasma cells in either bone or soft tissue, without evidence of multiple myeloma (MM), and whose prognosis is marked by a high risk of transformation to MM. EXPERIMENTAL

DESIGN:

We studied the impact of FDG-PET/CT (2[18F]fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography) on the risk of transformation of SP to overt MM among other markers in a series of 43 patients diagnosed with SP.

RESULTS:

Median age was 57.5 years; 48% of patients had an abnormal involved serum-free light chain (sFLC) value, and 64% had an abnormal sFLC ratio at diagnosis. Thirty-three percent had two or more hypermetabolic lesions on initial PET/CT, and 20% had two or more focal lesions on initial MRI. With a median follow-up of 50 months, 14 patients transformed to MM with a median time (TTMM) of 71 months. The risk factors that significantly shortened TTMM at diagnosis were two or more hypermetabolic lesions on PET/CT, abnormal sFLC ratio and involved sFLC, and to a lesser extent at completion of treatment, absence of normalized involved sFLC and PET/CT or MRI. In a multivariate analysis, abnormal initial involved sFLC [OR = 10; 95% confidence interval (CI), 1-87; P = 0.008] and PET/CT (OR = 5; 95% CI, 0-9; P = 0.032) independently shortened TTMM.

CONCLUSIONS:

An abnormal involved sFLC value and the presence of at least two hypermetabolic lesions on PET/CT at diagnosis of SP were the two predictors of early evolution to myeloma in our series. This data analysis will need confirmation in a larger study, and the study of these two risk factors may lead to a different management of patients with SP in the future. .
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Plasmacytoma / Bone Neoplasms / Tomography, X-Ray Computed / Cell Transformation, Neoplastic / Immunoglobulin Light Chains / Fluorodeoxyglucose F18 / Positron-Emission Tomography / Multiple Myeloma Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2014 Document type: Article Affiliation country: France Publication country: EEUU / ESTADOS UNIDOS / ESTADOS UNIDOS DA AMERICA / EUA / UNITED STATES / UNITED STATES OF AMERICA / US / USA

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Plasmacytoma / Bone Neoplasms / Tomography, X-Ray Computed / Cell Transformation, Neoplastic / Immunoglobulin Light Chains / Fluorodeoxyglucose F18 / Positron-Emission Tomography / Multiple Myeloma Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2014 Document type: Article Affiliation country: France Publication country: EEUU / ESTADOS UNIDOS / ESTADOS UNIDOS DA AMERICA / EUA / UNITED STATES / UNITED STATES OF AMERICA / US / USA